RxDoctor Payments Data

Abdul Malik, MD

Psychiatry · Towson, MDNPI 1255363339

Payments from drug & device makers

$1,512in general payments, 2019–2025

Across 80 payments — averaging $18.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$254
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$210
  • Otsuka America Pharmaceutical, Inc.$124
  • Teva Pharmaceuticals USA, Inc.$120
  • Sunovion Pharmaceuticals Inc.$118
  • Bausch Health US, LLC$86
  • plus $600 from 19 others

What the payments were for

  • Food & beverage$1,512100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,512 in reported general payments places this provider in the 80th percentile of 851 psychiatry providers in Maryland.

See all psychiatry providers in Maryland

Medicare billing

Part B allowed, 2024
$73,458
Medicare patients
137
Services billed
569

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aripiprazole61$4,822
Duloxetine Hcl110$3,502
Olanzapine93$3,498
Bupropion XlBupropion Hcl96$3,321
Venlafaxine Hcl ErVenlafaxine Hcl38$2,774
Buspirone Hcl101$2,509
Escitalopram Oxalate88$2,033
Atomoxetine Hcl22$1,946
Quetiapine Fumarate51$1,684
Trazodone Hcl97$1,647
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine45$1,530
Sertraline Hcl66$1,399
Desvenlafaxine Succinate ErDesvenlafaxine Succinate23$1,366
Divalproex Sodium44$1,296
Alprazolam97$1,271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Almatica Pharma LLCSertraline Hcl$29$1,39966 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 851 psychiatry providers in Maryland.

Other psychiatry in Towson

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →